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Abstract
Purpose of the study
This study seeks to explore methods for conducting economic evaluations alongside multi-
national trials by conducting a systematic review of the methods used in practice and the
challenges that are typically faced by the researchers who conducted the economic
evaluations.
Methods
A review was conducted for the period 2002 to 2012, with potentially relevant articles identi-
fied by searching the Medline, Embase and NHS EED databases. Studies were included if
they were full economic evaluations conducted alongside a multinational trial.
Results
A total of 44 studies out of a possible 2667 met the inclusion criteria. Methods used for the
analyses varied between studies, indicating a lack of consensus on how economic evalua-
tion alongside multinational studies should be carried out. The most common challenge
appeared to be related to addressing differences between countries, which potentially hin-
ders the generalisability and transferability of results. Other challenges reported included
inadequate sample sizes and choosing cost-effectiveness thresholds.
Conclusions
It is recommended that additional guidelines be developed to aid researchers in this area
and that these be based on an understanding of the challenges associated with multina-
tional trials and the strengths and limitations of alternative approaches. Guidelines should
focus on ensuring that results will aid decision makers in their individual countries.
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Introduction
Establishing whether new and existing health technologies provide value for money is becom-
ing important internationally, and many countries now require evidence on cost-effectiveness
for resource allocation decisions [1–2]. In the UK, the National Institute for Health and Care
Excellence appraises health technologies in terms of their clinical effectiveness and cost-effec-
tiveness [3], and economic evaluation, which is the comparison of alternatives in terms of costs
and benefits, is one of the tools used for this purpose [4]. Economic evaluations have been con-
ducted alongside trials mainly because they provide a means for collecting clinical and eco-
nomic data simultaneously. One type of trial that has seen an increase in its popularity, owing
to its ability to recruit participants rapidly and expedite the development of new health technol-
ogies, is the multinational trial, which is defined as a study that takes place in more than one
country or jurisdiction [5–9].
One of the reasons for pooling/aggregating clinical data from cross-country studies is the
belief that clinical and biological effects are homogenous across countries/jurisdictions [10].
However, the same cannot be said about economic data, owing to the vast differences in health
systems, practice patterns, resource use and unit prices between countries, all of which need to
be accounted for when conducting an economic evaluation [11–14]. Recent reviews of the liter-
ature revealed wide variation in the way these differences are addressed [15–16], indicating a
lack of consensus among researchers. Availability of economic data in some countries also
poses potential problems for researchers. A study conducted alongside a neurologic trial in 15
countries reported a dearth of unit cost information in some participating countries despite the
efforts that were made to obtain these costs [17]. Generalisability (applying the results of a
study to a number of countries without needing to adjust for interpretation) and transferability
(adapting the results of a study to other countries) are other challenges that have been identi-
fied in the literature [18]. In principle, because of their very nature, results from cross-country
studies should be more generalisable. However, it can be argued that pooled results cannot be
applied to a single country owing to the inclusion of data from different jurisdictions [19]. A
recent review of national guidelines on the use of data from multinational trials showed that
there were vast differences in the data different countries considered to be generalisable or
transferable to their settings [1], which indicates a lack of consensus among countries and
which potentially limits the usefulness of cost-effectiveness estimates from multinational trials
[19–20]. Resource allocation decisions are normally made at a national level [20–22], and thus
there is the need to develop and agree on appropriate methods for conducting and interpreting
economic analyses based on multinational trials. This would not only make results more useful
to decision makers but also avoid the duplication of work in every country/jurisdiction [2].
A number of methods have been developed in response to the challenges outlined, ranging
from very simple approaches such as adjusting resource use to very complex statistical
approaches such as multilevel modelling [22]. The extent to which these methods have been
used in practice is unclear. One study concluded that there is a need for more guidance as a
result of the vast variation in methods that are being used to conduct economic analyses along-
side multinational trials [15]. It is our belief that a study designed to assess the challenges
reported by researchers could lead to a better understanding of the reasons methods vary and
also help to develop additional guidance in this area. The objective of this study is to review
published economic evaluations that were conducted alongside multinational trials with the
aim of exploring methods that have been used and to outline researchers’ challenges i.e. any
difficulties associated with the multinational nature of the trial. As far as we are aware, no other
review has considered the challenges that have been reported by researchers who have con-
ducted economic evaluations alongside multinational trials.
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Materials and Methods
A systematic review was conducted following the guidelines of the Centre for Reviews and Dis-
seminations (CRD) [23].
Inclusion and exclusion criteria
Studies were included if they were full economic evaluations based on multinational trials and
reported an incremental cost-effectiveness ratio (ICER) or incremental net benefit. Studies
were excluded if they were modelling studies or systematic reviews, did not use patient-level
data or were not published in English.
Search strategy
The electronic databases searched were: MEDLINE, EMBASE and the National Health Service
economic evaluation database (NHS EED). The search was limited to the period 2002 to 2012
for pragmatic reasons and to capture the most recent studies. The following keywords were
used in the search: multinational, cost, cost-effectiveness, cost-utility, cost-benefit, multi-coun-
try, multi-centre, trial, economic evaluation, and cross-country (S1 Table). Following an
approach used by Roberts and colleagues [24], a three-stage process was used to select relevant
papers (S1 Text). The screening of papers was done by all reviewers. Stage one (categorization
of studies) was carried out by one reviewer who initially screened titles and abstracts of articles
and classified them into 5 groups. Stage 2 (further classification of studies) and stage 3 (applica-
tion of the inclusion criteria) were carried out independently by all three reviewers (see S1
Text). Results from each reviewer were compared and any differences were resolved through
consultation among all reviewers. The quality of the economic evaluations was not assessed
because of the study objectives and the need to include as many studies as possible.
Data Extraction
Data were extracted using a predefined data extraction form (S2 Table), and the following data
were extracted from the included studies: Type of economic evaluation, health outcomes con-
sidered, study perspective, number of countries included, analytical approach to the economic
evaluation used and challenges faced.
Results
The database searches yielded 2667 articles. After accounting for duplicates, 997 were excluded.
Inspecting the titles and abstracts of the remaining papers yielded 114 potentially relevant arti-
cles, of which 62 were classified as economic evaluations that reported an ICER or incremental
net benefit. Of these, 39 met the inclusion criteria and the remaining 23 were excluded mainly
because they were model-based (20 studies) or not relevant (3 studies). An additional 5 studies
were identified through cross referencing. Forty-four studies were included in the final sample
(Fig 1).
Summary of selected studies
The types of economic evaluations were mainly cost-effectiveness analysis (31 studies) and
cost-utility analysis (18 studies) (Table 1). Of these, 5 studies conducted both [25–29]. In one
study, cost-utility analysis was performed as secondary analysis but an ICER was not estimated
[25]. Sixteen studies were related to cardiovascular disease, representing a substantial propor-
tion of the included papers. A total of 21 trials were placebo controlled (Table 2), with a com-
mon characteristic being their assessment of drug therapies. The number of countries included
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in an individual trial ranged from 2 to 48, and approximately 80% of studies included in the
review recruited patients from the UK (S3 Table). Using World Bank classifications [30], we
identified 38 high-income, 24 upper middle-income, 12 lower middle-income and only 5 low-
income countries (S3 Table). Only 2 studies included participants from low-income countries:
one that assessed interventions for preeclampsia [31] and another that evaluated a malaria
intervention [32]. Studies that recruited patients from lower middle-income countries primar-
ily assessed interventions for chronic obstructive pulmonary disorder and asthma [33–36].
Health outcomes
Studies that adopted the CEA approach reported general outcomes such as cost per life year
gained or used disease-specific outcome measures such as cost per cardiovascular event
avoided. The quality adjusted life year (QALY) was the main outcome measure for those that
Fig 1. Literature search and selection.
doi:10.1371/journal.pone.0131949.g001
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Table 2. Specific characteristics of studies included in the review.
Author Placebo controlled trial Provided sources of unit costs in each country Currency used
Pounds Euro US dollar Other
Canoui-Piotrine et al 2009 [25] ✗ ✗ ✓
Glasziou et al 2010 [26] ✓ ✗ ✓
Marcoff et al 2009 [27] ✗ ✗ ✓
Mittman et al 2009 [28] ✗ ✗ ✓
Reed et al 2004 [29] ✓ ✗ ✓
Simon et al 2006 [31] ✓ ✗ ✓
Lubell et al 2009 [32] ✗ ✗ ✓
Sullivan et al. 2003 [33] ✗ ✗ ✓
Briggs et al 2006 [34] ✗ ✗ ✓
Briggs et al 2010 [35] ✓ ✗ ✓
Lofdal et al 2005 [36] ✓ ✗ ✓
Bachert et al 2007 [37] ✓ ✓ ✓
Canonica et al 2007 [38] ✓ ✓ ✓
Fernandez et al 2005 [39] ✗ ✗ ✓
Manca et al 2003 [40] ✗ ✗ ✓
Garry et al. 2004 [41] ✗ ✗ ✓
Nasser et al. 2008 [42] ✓ ✗ ✓
Bracco et al 2007 [43] ✓ ✗ ✓
Knapp et al 2008 [44] ✗ ✗ ✓
Buxton et al 2004 [46] ✓ ✓ ✓
Rutten Von Molken et al 2007 [47] ✓ ✗ ✓
Willan et al 2006 [48] ✓ ✓ ✓ ✓
Ra✓deva et al 2005 [49] ✗ ✗ ✓
Edbrooke et al 2011 [50] ✗ ✗ ✓
Lamy et al 2004 [51] ✓ ✗ ✓ ✓ ✓ ✓
Drummond et al 2003 [52] ✗ ✗ ✓
Gomes et al. 2010 [53] ✗ ✗ ✓
Lorgelly et al 2010 [55] ✗ ✗ ✓
Price et al 2002 [57] ✗ ✗ ✓
Weintraub et al 2005 [58] ✓ ✗ ✓
Wade et al 2008 [59] ✗ ✗ ✓
Kolm 2007 [60] ✓ ✗ ✓
Jowett et al 2009 [61] ✗ ✗ ✓
Dukhovny et al 2011 [62] ✓ ✗ ✓
Annemans et al 2003 [81] ✗ ✗ ✓
Aspelin et al 2005 [82] ✗ ✗ ✓
Bakhai et al. 2003 [83] ✗ ✗ ✓
Brown et al. 2003 [84] ✗ ✗ ✓
Janzon et al 2003[85] ✓ ✗ ✓ ✓
Lamy et al 2003 [86] ✓ ✗ ✓
Lindgren et al. 2005 [87] ✗ ✗ ✓
Martin et al 2003 [88] ✓ ✗ ✓
Reed et al. 2004 [89] ✓ ✗ ✓
Welsch et al 2009 [90] ✓ ✗ ✓
doi:10.1371/journal.pone.0131949.t002
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used CUA; however, different methods were used to estimate QALYs. The main approach
was to obtain responses to the EQ-5D questionnaire and use them to obtain health utilities
(Table 1). Nine studies gave an indication of how they generated EQ-5D index scores [35, 37–
44], and in all cases, the UK tariff [45] was used, mainly because it was well established [43],
recommended [35] and readily available [44]. Only one study used the Health Utility Index to
obtain QALYs [28]. Mapping was another approach used for this purpose; one study used a
mapping algorithm to obtain QALYs from the Asthma Quality of Life Questionnaire [34].
Costing and study perspective
Twenty-eight studies applied unit costs from only one country to the data; the others applied
unit costs from all or a subset of countries (Table 1). The average number (range) of countries
per study was 17 (2 to 48) and 16 (4 to 42) for studies that adopted the one-country and multi-
country approaches, respectively. One reason for adopting a one-country costing approach was
the availability of good-quality data in countries such as the UK [44]. Most studies presented
results from one perspective (health service/healthcare or societal) (Table 1), although three
adopted multiple perspectives for the purpose of comparison [33,46–47]. The results obtained
from the different perspectives were comparable [33,47], although one study had results that
were sensitive to the perspective adopted [46]. In terms of what was considered societal costs,
most studies included productivity losses using human capital [33, 37, 38, 42, 46] or friction
costs approaches [47]. One study included caregiver time [48], whereas others were not explicit
about what was included.
The level of detail given about the sources of unit costs varied from simply stating that offi-
cial tariffs and retail prices in each country had been used [37] to providing detailed references
of each country’s unit costs [25,46,48]. In most cases, it was unclear how costs had been
obtained (Table 2). One approach to costing when unit costs were unavailable was to assume
that countries were similar in terms of geographic proximity and level of development and
apply the mean cost from countries that were assumed to be similar to the countries for which
costs were not available [31,49]. In contrast, the market basket approach, which involves devel-
oping an index that reflects the relative costs of a basket of resources used in a pair of countries
[17], was used in two studies [29,49]. Other approaches included using recognized interna-
tional databases such as the WHO-CHOICE database [32], contacting local health economists
and researchers through surveys that elicited unit cost information [29,49] and the top-down/
macro-costing approach, which considers costs at an aggregate level [50]. This approach has
been shown to be effective in cases when obtaining unit costs is not feasible [4]. Some studies
used a combination of methods, such as using the market basket approach and contacting local
researchers [29, 49]. In terms of presenting costs, the most common currencies used were the
US dollar, the Euro and the UK pound, with one study [51] presenting its results using more
than one currency (Table 2).
Analytical approach to economic evaluation
Based on a well-known classification system (S2 Text) [19], 26 studies were classified as fully
pooled one-country costing, and 13 were fully pooled multi-country costing studies. Some
studies adopted the fully split approach, with 60% of these using one-country costing. One
study was classified as a partially split multi-country costing study (S4 Table). The justification
for pooling data was that the sample size in some participating countries was too small [37,38],
but only one study tested whether it was appropriate to pool data across countries [52].
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Methods for addressing the multinational nature of the data and ensuring
the generalisability and transferability of results
Estimating country-specific cost-effectiveness. Two studies used subgroup analysis
within sensitivity analysis to estimate ICERs using only data from the country of interest
[26,53], and in both cases, the results were similar to the main (pooled) analysis. A third study
ignored data from all other countries and used data from only the country of interest [25].
Empirical Bayesian shrinkage, a method that involves borrowing strength from the overall trial
to estimate country-specific cost-effectiveness [54], was used by only one study; however, the
authors did not present the country-specific estimates [27]. The simplest approach was to state
that the perspective of the analysis was related to a particular country and to apply unit costs
from that country to the trial-wide data [34, 36, 37, 46, 52]. With regard to reporting the coun-
try-specific results, one study [51] reported the cost-effectiveness results in the country’s own
currency, whereas other studies presented their results in currencies such as US dollars or
Euros.
Regression methods. Multilevel modelling was used in three studies to account for the
clustered nature of the data [27, 49, 50]. Other regression approaches such as controlling for
country when estimating outcomes such as the QALY [43], adjusting for length of stay and
costs within countries [51] and including interaction terms and country dummy variables
[34,39,44,52] were also used. In one of the studies, the authors went further to test whether the
country dummy variables were significant [39].
Other approaches. Event rather than daily costs were used to eliminate effects such as dif-
ferences in lengths of stay across countries [51,55]. Close adherence to the study protocol [56]
was also used to eliminate differences in practice patterns and resource use in different coun-
tries [36]. One study made assumptions about the number of visits per patient to reflect current
guidelines and the UK Department of Health’s recommendations for the management of
asthma [57].
Challenges associated with the economic evaluation of multinational
trials
Potential challenges were discussed in 29 studies (Table 1), including:
Differences between countries. It was noted that there are numerous differences between
countries but no accepted guidance on how to account for them [35, 46, 53]. These differences
include: differences in resource use, prices, health systems and practice patterns [27–
29,31,39,46,47,52,54,58–60]. Estimating country-specific cost-effectiveness was another area in
which there is no consensus amongst researchers [35,46]. One study acknowledged this and
outlined the advantages and disadvantages of some of the approaches that had been suggested
in the literature [35].
Sample size and lack of data. Sample size problems were mentioned by some researchers,
who noted that uneven recruitment across countries could potentially lead to unreliable cost-
effectiveness estimates, especially in cases in which pooling data across all countries is not an
option [31, 32, 35, 37, 46]. The lack of country-specific price weights/costs and the challenges
associated with collecting data in multi-country studies were also highlighted in some studies
[49, 59, 61]. Most often, the researchers conducting the economic analysis were based in one
country and were unlikely to know the sources of unit costs in other countries. In addition,
there is also a lack of good-quality data in some participating countries, particularly in develop-
ing countries [29, 44, 62]. One study was aware of the advantage of using country-specific price
weights but went on to use price weights from only one country [62].
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Additional challenges. The cost-effectiveness threshold, which represents society’s will-
ingness to pay for an additional unit of benefit, is often used to determine whether an interven-
tion is cost-effective [63]. However, with regard to analyzing multinational trials, researchers
are faced with the problem of how to determine and choose the appropriate threshold [28, 34,
43, 46]. One study adopted a threshold of €50,000 per QALY but stated that the decision was
based on what other studies had done in the past [43]. Another important issue relates to the
generalisability of study findings. Two studies noted that owing to the multinational nature of
the data, decision makers in various countries might face problems with making judgments
about the cost-effectiveness of interventions in their own country/jurisdiction [29, 35]. Finally,
only one study mentioned the choice of the EQ-5D tariff as a challenge [44].
Discussion
Summary of main findings
This review has assessed published economic evaluations that were conducted alongside multi-
national trials. The results indicate that most studies applied costs from one country but
resource use from all countries, possibly owing to a lack of cost data in some countries or to the
fact that researchers sought to inform decisions in a particular country. However, of the studies
that reported results from a single country, 50% of them applied one-country costing. The
major problem that has been associated with this approach is the possibility of overestimating
or underestimating costs [19, 22, 64].
Most studies did not give reasons for having pooled resource use and effectiveness data,
although it can be inferred that increasing sample size is a possible motivation for this. One
study did test for heterogeneity and homogeneity before pooling data [53]. With regard to
pooling resource use, unless the study protocol is followed rigidly, issues related to practice pat-
terns across countries could potentially affect the analysis [19]. However, it should be noted
that although protocols have the potential to reduce differences in treatment patterns across
countries, they do not necessarily dictate all care provided.
The UK tariff was used in all studies that used the EQ-5D questionnaire to elicit information
on health-related quality of life, and although its widespread use can be attributed to its avail-
ability [35, 43, 44], it is also possible that other tariffs such as the EU tariff, which was derived
from 6 countries, were not used because they are based on the visual analogue scale (VAS).
Although some researchers believe that the VAS should not be used in resource allocation deci-
sions because the values obtained are not considered to be utilities [65–67], current research is
exploring the predictive value of the EQ-VAS for EQ-5D utilities [68]. In addition to this, most
of the studies that used the UK tariff over the EU tariff were published after 2003, the year the
EU tariff was published. This supports the findings from other research papers that the UK tar-
iff is most often used [67]. The choice of the EQ-5D tariff is important because different tariffs
could lead to conflicting results [69], and the EuroQol group’s current guidance states that the
most relevant should be used [70]. However, when the study is multinational, it is difficult to
determine the most relevant tariff, and thus, there is a need for further research. A recent study
has suggested that researchers explore the potential for different results using all appropriate
tariffs within sensitivity analyses [71].
A number of studies made some form of adjustment to the data to account for the multina-
tional nature; however, the methods used varied, indicating that methods have not been stan-
dardized in this area. With regard to studies that looked at country-specific results, only one
study explicitly stated that the reason for doing this was the important role of health economics
in policy making [46]. The most common method of obtaining country-specific estimates was
fully pooled one-country costing. Current recommendations by the ISPOR taskforce suggest
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that the more complex methods such as hierarchical modeling should be used for the analysis
of multinational trial data [18] and a recent study also concluded that Bayesian hierarchical
models are the most appropriate for estimating country-specific cost-effectiveness [22]; how-
ever, only one study in this review used this approach [27], suggesting that researchers are not
adhering to existing guidelines, possibly because of the complexity associated with implement-
ing this approach. Bayesian hierarchical models have been challenged because it assumes that
differences between countries are random, whereas in reality, these differences are systematic
[72].
The multinational nature of the data was acknowledged by most studies, but not all listed
the countries that were included, and some merely reported the number of countries in the
trial. This may be attributable to word limits imposed by journals. In most cases, it was not
clear whether the study was attempting to estimate general or country-specific results, primar-
ily as a result of inadequate reporting. With respect to unit costs, we found that the sources of
the costs were not stated in most cases. This is of great concern because this information would
enable researchers and decision makers to judge the validity of the study and whether it was
applicable to their own settings and also help other researchers identify unit cost sources. It is
therefore advisable that future multinational studies include unit cost sources, and if assump-
tions about the unit costs were made, this should also be made explicit. This review also found
that recruitment is biased towards developed countries, which may reflect the difficulties asso-
ciated with recruiting patients and the lack of high-quality data in low-income countries [44].
Comparison with other studies. Other reviews have looked at economic evaluations
alongside multinational trials and obtained results similar to what was found in our study. One
study found that reporting on economic evaluations of multinational trials is inadequate [16],
another found that methods of analysis differed between studies [15] and a recent review
reported that the uptake of the more complicated methods for estimating country-specific
cost-effectiveness is slow [73].
Strengths and limitations of the study. As with any systematic review, there is the possi-
bility that some articles may have been missed. However, we made the best attempt to identify
all possible studies by developing the search strategy with advice from an information special-
ist. The key strength of this study is that it documented the challenges that have been reported
by researchers who have conducted economic evaluations of clinical trials, and no other sys-
tematic review of multinational trials has done this.
Implications for current practice and future research. The most frequently mentioned
challenge was the differences between countries, which could possibly affect the generalisability
of study findings. Most clinical results from multinational trials are generalisable to the coun-
tries that participated in the study. However, results from economic evaluations are not easily
generalisable [1] because there are differences in economic circumstances and differences in
health systems across various countries. Hence, there is the need to consider these issues when
countries are being included in trials. However, the requirements for economic evaluation/
analysis are not given prominence when countries are being chosen for inclusion in multina-
tional trials, and country selection is based on factors such as convenience [2,22]. Research is
ongoing regarding selecting centres for multi-centre clinical trials [74], but this research needs
to be extended to selecting countries in multinational trials as well because the countries
included in a study could potentially determine the extent to which the study results are gener-
alisable. In addition, a very important finding is that different methods were used by different
studies for costing and addressing differences between countries. This is an indication that
guidance similar to that which has been developed for standard economic evaluations needs to
be developed. Although it can be argued that data from multinational trials may only serve as
inputs into decision models which are used in resource allocation decisions at the national
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level, there is still the need to develop methods that would ensure that these inputs can be
made more generalisable and transferable to individual country contexts when the need arises.
A possible solution to the problem of generalisability and transferability is the use of check-
lists to ensure that the results meet the required standards [75–78]. However, a possible limita-
tion is the fact that individual items on checklists are sometimes equally weighted [79].
Another suggestion is for researchers to conduct economic evaluations using multiple perspec-
tives. For example, the results of a study that considers both a health service and societal per-
spective may be useful for decision making in both the UK and the Netherlands.
There is evidence from this study that most researchers are aware of some of the issues sur-
rounding economic evaluation alongside multinational trials, but they did not offer solutions
to these challenges in most cases. Researchers should therefore endeavor to document the chal-
lenges they face to guide future research. The main challenge we identified was how to address
the differences between countries, which could be attributed to a lack of consensus on many
aspects such as how to estimate country-specific cost-effectiveness. Future research should
therefore focus on reaching a consensus about how to address the challenges associated with
multinational trials.
Conclusion
Despite the difficulties associated with multinational studies, their frequency will increase [80].
It is clear that conducting an economic evaluation in every country/jurisdiction is not feasible
or efficient, and decision makers are likely to have to resort in some cases to considering results
from other countries/jurisdictions to inform their local decision making despite the obvious
limitations. Conducting economic evaluations alongside multinational trials is not trivial, and
there should be a conscious effort by all stakeholders to constantly improve methodology in
this area. We suggest that additional guidelines be developed to aid in using a consistent
approach in this area, and this should be based on understanding the challenges associated
with multinational trials and comparing alternative approaches. The guidelines should also be
focused on ensuring that results can be useful to decision makers in individual countries.
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